Developing a core outcome set for foot and ankle disorders in rheumatic and musculoskeletal diseases: A scoping review and report from the OMERACT 2022 foot and ankle special interest group session
Authors' conclusion
Findings from the scoping review and feedback from the SIG will contribute to the development of a core outcome set for foot and ankle disorders in RMDs.
Study context
- Population
- Clinical trials and observational studies of pharmacological, conservative or surgical interventions in adults with foot or ankle disorders in rheumatoid arthritis (RA), osteoarthritis (OA), spondyloarthropathies, crystal arthropathies and connective tissue diseases
- Participants
- 150 eligible studies
- Outcome
- Outcome domains measured in included studies
Methodological detailsoutcome domains categorised by OMERACT Filter 2.1, virtual OMERACT Special Interest Group (SIG), October 2022, Feedback sought from SIG delegates on scope of the core outcome set and next steps, including focus group and Delphi methods
- Outcome domains categorised by OMERACT Filter 2.1
- Virtual OMERACT SIG, October 2022
- Feedback sought from SIG delegates on scope of the core outcome set and next steps, including focus group and Delphi methods
Main finding
As reported in the abstract
Studies including foot/ankle OA
63%
Studies including foot/ankle involvement in RA
29%
Foot/ankle pain, most commonly measured outcome domain, most frequently specified across all rheumatic and musculoskeletal diseases (RMDs)
78%
Original publication
Developing a core outcome set for foot and ankle disorders in rheumatic and musculoskeletal diseases: A scoping review and report from the OMERACT 2022 foot and ankle special interest group session. Semin Arthritis Rheum. Published 4 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →